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ABSTRAK
Latar belakang: skleroderma merupakan penyakit autoimun yang resisten terhadap pengobatan standar, 
penambahan ekstrak herba ciplukan (Physalis angulata Linn) diduga dapat memperbaiki fibrosis kulit skleroderma. 
Penelitian ini bertujuan mengkaji peran ekstrak herba Ciplukan sebagai terapi ajuvan untuk fibrosis kulit 
skleroderma yang mendapat terapi standar, berdasarkan MRSS, biomarker inflamasi, imunologi dan fibrosis 
serum. Metode: uji klinis acak tersamar ganda pada pasien skleroderma stabil yang berobat jalan di RSCM dan 
RSHS sejak November 2015−Maret 2017 yang memenuhi kriteria inklusi dan menerima terapi standar. Subjek 
secara random terbagi dua: kelompok uji yang mendapat ekstrak herba C iplukan 3x 250 mg/hari selama 12 
minggu dan kelompok plasebo. Pemeriksaan MRSS, LED, P1NP, BAFF dan sCD40L dilakukan setiap 4 minggu 
hingga akhir penelitian. Hasil: lima puluh sembilan subjek menyelesaikan penelitian, 29 subjek kelompok uji dan 
30 subjek kelompok plasebo, rerata usia 41 (SB 9) tahun, proporsi wanita : pria = 9 : 1. Ditemukan perbaikan 
fibrosis kulit bermakna pada kelompok uji dengan penurunan relatif MRSS sebesar 35,9% dibandingkan plasebo 
6,3% dengan p < 0,001 dan penurunan relatif bermakna kadar P1NP sebesar 17,8% dibandingkan plasebo 0,7% 
dengan p = 0,002. Tidak ditemukan penurunan kadar LED, BAFF dan sCD40L pada kedua kelompok. Terdapat 
korelasi positif bermakna antara MRSS dengan kadar P1NP (r = 0,236, p = 0,036). Kesimpulan: pemberian 
ekstrak etanol herba ciplukan dosis 3 x 250 mg selama 12 minggu sebagai terapi ajuvan pada skleroderma dalam 
terapi standar, secara klinis dan statistik menunjukkan perbaikan kelainan fibrosis kulit berdasarkan MRSS dan 
biomarker fibrosis P1NP serum secara bermakna dibandingkan kontrol.
Kata kunci: Physalis angulata Linn, modified Rodnan’s skin score (MRSS), erythrocyte sedimentation rate 
(ESR), procollagen type-1 N terminal proteinase (P1NP), skleroderma.
ABSTRACT
Background: scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard 
treatment. It is suggested that he addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can 
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improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on 
scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, 
immunology and serum fibrosis. Methods: double-blind, randomized clinical trial was performed in scleroderma 
patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015−
March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly 
allocated into two groups: the study group received the ciplukan  extract 3 x 250 mg / day for 12 weeks and the 
placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end 
of the study. Results: fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 
30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1. There was 
a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 
6.3%, p <0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF 
and sCD40L levels were observed in both groups. There was a weak but significant positive correlation between 
MRSS with P1NP levels (r=0.236, p=0.036). Conclusion: Ciplukan extract with dose 3 x 250 mg for 12 weeks as 
adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels.
Keywords: Physalis angulata Linn, modified Rodnan’s skin score (MRSS), erythrocyte sedimentation rate 
(ESR), procollagen type-1 N terminal proteinase (P1NP), scleroderma.
INTRODUCTION
Scleroderma is an autoimmune connective 
tissue disease involving fibrosis of the skin, which 
is characterized by the excessive accumulation 
of extracellular matrix (ECM) proteins, vascular 
injuries, and immune abnormalities. In early 
stages of scleroderma, activated fibroblasts in the 
affected areas produce high amounts of collagen.1 
Numerous studies have demonstrated the crucial 
role of several fibrogenic cytokines released 
from immunocytes in initiating the sequence of 
events leading to fibrosis in the pathogenesis of 
scleroderma.1,2 Moreover, vascular injury and 
apoptosis, extracellular matrix overproduction, 
oxidative stress (reactive oxygen species) 
also played role.1,2,3-5 The standard therapy for 
scleroderma is modifying disease anti-rheumatic 
drugs (DMARD).6 However, there are some 
problems such as high risk of drugs resistance; 
drug side effects, and price of the drug.2,6 Some 
immunosuppresant agents are not covered by 
the national health insurance. Therefore, some 
patients discontinue the treatment, resulting 
in disease progresses, higher morbidities, and 
mortality. Some new medicines are still under 
research and not accessible. Others are too 
expensive for most of Indonesian communities.
Ciplukan herb (Physalis angulata Linn.) 
is known widely as a medicinal plant. It 
grows in Indonesia and has been known 
for its efficacy to stimulate the activity of 
lymphocyte, and modulate the immune system 
in human.7-8 Ciplukan herb is also known for 
its antiinflamatory, antiproliferative, anti-
angiogenesis, and anti-cancer activities because 
it contains phenol, secosteroid (physalin, 
withanguline, and others), and saponin. It has 
three major pathways in immunomodulatory. The 
first pathway is phenol components in Ciplukan 
herb, such as flavonoid, tannin, phenylpropane, 
and other simple phenol compounds which 
show antioxidant and immunomodulating 
effects that control the autoimmune activity.8-10 
The second and third pathways are due to 
secosteroid and saponin compounds which have 
anti-inflammatory and antiproliferative effects 
that is thought to inhibit the fibrosis process in 
scleroderma.10-12 Ciplukan herb is proved to be 
safe in human. No side effects were reported in 
long-term use.8-9
There are no published clinical trials 
regarding the effects of ciplukan herb on 
scleroderma, in terms of skin fibrosis changes 
based on MRSS and the level of biomarkers 
serum in scleroderma. The aim of this study to 
evaluate the effect of the addition ciplukan extract 
as adjuvant to scleroderma standard therapy in 
suppressing inflammatory, immunological, 
and fibrosis processes to accelerate clinical 
improvement of skin fibrosis based on MRSS in 
Vol 51 • Number 4 • October 2019     A double blind, randomized controlled trial of ciplukan extract on skin fibrosis
305
scleroderma patients (primary outcome).13-14 We 
evaluated disease activity based on erythrocyte 
sedimentation rate for inflammatory biomarker; 
the levels of B-cell activation factor (BAFF) 
and soluble CD40 ligand (sCD40L) serum 
for immunological biomarkers; and the level 
of procollagen Type I N-Terminal Propeptide 
(P1NP) serum for biomarker of fibrotic process 
(secondary outcome).15-22
METHODS
This was a randomized, double blind, 
placebo controlled trial. Subjects were recruited 
consecutively from January 2016 to March 2017. 
This study has been approved by the Ethical 
Research Comission of Faculty of Medicine 
Universitas Indonesia and Research unit of 
Cipto Mangunkusumo Hospital (25/UN2.F1/
ETIK/2016).
Subjects
Inclusion criteria were limited and diffused 
type of scleroderma patients in rheumatology 
outpatient clinic in Cipto Mangunkusumo 
Hospital (RSCM) or Hasan Sadikin Hospital 
(RSHS) Bandung, aged 15−60 years old, 
received standard therapy with stable dose in 
the last 3 months. Exclusion criteria were not 
willing to participate in the study, impaired liver 
function or cirrhosis, impaired renal function, 
overlap syndrome, active tuberculosis, heart 
disease, allergy to Ciplukan herb or history of 
hypersensitivity to certain drugs, hypotension 
and hypoglycemia.
Subjects with consent for clinical trials were 
randomly assigned into 2 groups: intervention 
group (ciplukan herb 250 mg TID) or control 
group (placebo containing amylum 250 mg TID). 
Subjects were observed for 12 weeks. Allocation 
was done using block permuted randomization 
technique with block size combination 4. 
The result was put in sealed envelopes. The 
researchers, responsible physicians, and study 
subjects did not know the allocation group until 
the end of the study (double-blind).
Data Collection and Analysis
Collected data included demographic data 
(age, sex, weight, height, blood pressure), 
clinical data (duration of illness, history of illness 
and medication), skin fibrosis examination based 
on MRSS, and laboratory examination: ESR, 
the levels of P1NP, BAFF and sCD40L serum, 
complete blood count, transaminase enzyme, 
creatinine, blood glucose, sodium, potassium 
and urinalysis. All data were collected every 4 
weeks during the visit. We also assessed subjects’ 
compliance and adverse event during treatment. 
Normally distributed data was presented 
in mean (SD); otherwise, presented in median 
(interquartile range). A 95% confidence interval 
(95% CI) was calculated around scleroderma-
prevalence. Comparison between groups was 
done using Mann-Whitney U test. Data were 
analyzed using SPSS program. Drop out subjects 
were removed from the analysis (per protocol) 
to see the main output. Efficacy of the drugs 
was represented using the result of intention to 
treat  (ITT) and number needed to harm (NNH). 
The main outcome of clinical assessment, 
improvement of skin fibrosis based on MRSS 
was analyzed using unpaired t-test, to assess the 
different effects between ciplukan herb group 
and placebo group. For the secondary outcome, 
numeric variables such as the level of ESR, 
BAFF, sCD40L, P1NP, and the relative changes 
of those variables after 12 weeks of treatment 
were analyzed using Wilcoxon  test. 
This study was conducted based on  the 
principles of the “Guideline for Good Clinical 
Practice” of the ICH Tripartite Guideline (ICH-
GCP). This study has been registered in the 
registry of clinical trial data at www.clinicaltrials.
gov with ClinicalTrials.gov ID: NCT03141125 
identification number to ensure the public 
scientific knowledge of this research.
RESULTS
Baseline Characteristics
There were 61 subjects randomly allocated 
into 2 groups. After 12 weeks of observation, 
one subject dropped out in ciplukan group due 
to loss to follow-up. In placebo group, one 
subject dropped out due to severe hypoglycemia. 
(Figure 1)
From 59 subjects, 92.1% were females 
with mean age of 41 (9) years old. Duration 
of scleroderma was 12 months to 88 months 
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Figure 1. Flow of subjects
with the median of 34 months. Subjects were 
categorized into 35 subjects (59%) diffuse type 
scleroderma and 24 subjects (41%) limited type 
scleroderma. Diffuse type scleroderma were 
higher in intervention group (65.5%) than in 
placebo group (53.3%), the other subjects were 
categorized into limited-type scleroderma. (Table 
1)
The most common encountered ACR EULAR 
diagnostic criteria 2013 clinical symptoms 
were finger fibrosis (100%), and Raynaud’s 
phenomenon (100%), followed by scars in 
36 (61%) subjects, finger ulcers in 32 (54%) 
subjects, salt and pepper appearance in 32 (54%) 
subjects, finger edema in 54 (91.5%) subjects, and 
telangiectasia in 17 (28.8%) subjects.
Initial assessment of modified Rodnan’s Skin 
Score (MRSS) showed higher score in ciplukan 
group (median 19, range 8−34) compared to 
placebo group (median 15, range 6−36). This 
is caused by the diffuse type of scleroderma 
subjects in ciplukan group were higher than 
in placebo group with the ratio of 19:16. This 
is consistent with the extent of skin fibrosis 
predilection in diffuse type than in the limited 
type of scleroderma.
The result of laboratory tests at the baseline 
of the study were as followed: the average of 
ESR was 38 (22) mm/hour; P1NP level was 56.8 
(31.8) ng/mL; BAFF level was 1,258 (5,473) pg/
mL; and serum sCD40L level was 6,505 (3,415) 
pg/mL.
Response to Ciplukan Herb 
Changes in skin abnormalities in the study 
subjects marked by a decrease in MRSS were 
shown in Figures 2 and 3.
MRSS decreased 35.9% in the ciplukan 
group, while it only decreased 6.3% in placebo 
group after 12 weeks. It means that Ciplukan herb 
can improve skin fibrosis clinically (Figure 4). 
Further decrease of serum P1NP levels 
were also found in ciplukan herb group (17.8%) 
compared to the placebo group (0.7%) after 12 
weeks (Figure 5). The response was better than 
the standard therapy alone.
There were no significant changes of the ESR 
value, serum BAFF, and sCD40L level in both 
groups. However we found that in placebo group, 
those values tend to increase compared to the 
baseline, but it was not statistically significant.
Bivariate analysis of skin fibrosis based on 
MRSS showed a weak correlation with serum 
P1NP level (r = 0.236; p = 0.036).
DISCUSSION
The previous study at Laboratorium 
Penelitian dan Pengujian Terpadu Universitas 
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Mean age,  
years (SD) 41 (9) 41 (9)
Gender, n (%)
 - Male 0 (0.0) 2 (9.5)
 - Female 29 (100) 29 (90.5)
Type of Scleroderma, n (%)
 - Limited type 10 (34.5) 14 (46.7)
 - Difuse type 19 (65.5) 16 (53.3)
Onset of the disease 
(months), median 
(IQR)
34 (12–88) 31 (13–72)
BMI (kg/m2),  
mean (SD) 20.7 (3.7) 20.1 (2.5)
Standard Therapy, n (%)
 - metothrexate 28 (96.6) 28 (93.3)
 - sulphasalazine 1 (3.4) 1 (3.3)
 - mycophenolat 
mofetil 1 (3.4) 1 (3.3)
 - colchicine 2 (6.8) 2 (6.6)
 - nifedipin 12 (41.4) 14 (46.7)
 - diltiazem 6 (20.7) 5 (16.7)
 - amlodipine 11 (37.9) 10 (33.3)
 - methylprednisolon: 
< 10 mg/day 15 (51.7) 16 (53.3)
 - aspirin 24 (82.7) 22 (73.3)
 - clopidogrel 3 (10.3) 4 (13.3)
 - cilostazol 2 (6.8) 1 (3.3)
 - folic acid 28 (96.6) 28 (93.3)
MRSS, median (IQR) 19 (8–34) 15 (6–36)
ESR (mm/hour), 
mean (SD) 35 (19) 40 (25)
BAFF (pg/mL),  
mean (SD) 1,132 (435) 1,380 (621)
P1NP (ng/mL),  
mean (SD) 50.5 (24.5) 62.9 (37)
sCD40L (pg/mL), 
mean (SD) 6,870 (4,125) 6,151 (2,576)
SD= Standard deviation; ESR= Erythrocyte sedimentation 
rate; MRSS= Modified Rodnan’s Skin Score; BAFF= β cell 
activating factor; P1NP= Procollagen type-1 N terminal 
proteinase; sCD40L= soluble cluster of differentiation 40 
Ligand.
Figure 2. Skin of scleroderma patients before study.
Figure 3. The skin of a scleroderma patient after completion 
of clinical trials (archive after open label) in the Ciplukan 
group.
Gadjah Mada (LPPT UGM) Yogyakarta, 
Ciplukan herb contained unspecific compounds, 
such as: Betasitosterols, tannins, phenols, 
saponins, flavonoids, and  alkaloids.
Phenolic compounds like flavonoid, 
tannin, phenilpropan, and other phenols have 
immunomodulatory activity with complement 
system or intracellullar biochemistry reaction. 
Ethanol extract is capable of extracting more 
phenols, flavonoids, and tannins than methanol 
and hexsane do. This study used 50% ethanol 
extract, which contains the highest total phenols 
compared to other solvents. The saponins 
component in herbal plants is known to have a 
potentiating effect on chemotherapy drugs such 
as methotrexate.25
Several studies have shown that ethanol 
extract from ciplukan herb has a strong 
antioxidant effect due to the flavonoid content. 
Phenol derivatives of ciplukan herb have an 
important role as natural theurapeutic substances 
that can inhibit oxidative stress in chronic 
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chemotaxis effect on neutrophils, causing direct 
damage to the cells.12 Other proinflammatory 
markers that need further investigation are 
Interleukin-6 and C-reactive protein (CRP), 
which increase in the inflammatory phase. 
Assessment of cyclooxygenase-1 (COX-1) 
and cyclooxygenase-2 (COX-2) activities 
may also be considered for follow-up studies, 
because both of them are involved in the 
inflammatory process. Inhibition of this COX 
enzyme causes a decrease in arachidonic acid 
levels, by alteration of arachidonic acid into 
eicosanoid, prostaglandin and thromboxane in 
the inflammatory pathway.11,12
There are several novelties and strengths in 
this study. First, to the best of our knowledge, 
this is the first clinical trial in the world that 
investigated the effects of ciplukan herb extract 
as adjuvant therapy, i.e. adding traditional herb 
to the standard therapy on scleroderma patients. 
Figure 4. Difference of MRSS changes from Physalis angulata and placebo group.
Figure 5. Difference of P1NP changes from Physalis angulata and Placebo group.
inflammatory diseases such as scleroderma.26-27 
Inflammatory processes and oxidative stress have 
been shown to play a role in the pathogenesis of 
scleroderma. The antioxidant ability of phenols 
can also protect lymphocytes from the adverse 
effects of reactive oxygen molecules. The 
component is soluble in a polar solvent, inducing 
leukocytes proliferation, increased lymphocytes 
proliferation is influenced by several factors 
such as the phenols content attached to proteins 
forming a protein complex that binds to the 
hydrogen ions. Sitosterol in ciplukan herb, 
has a strong anti-inflammatory effect and may 
contribute to the clinical improvement of 
scleroderma patients.11-12
The exact role of proinflammatory markers 
in ciplukan herb such as thromboxane B2 
(TXB2) and leukotriene B4 (LTB4) remains 
to be elucidated. TXB2 has the ability to 
increase platelet aggregation and LTB4 has a 
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Second, ethanol extract has the highest content 
of phenols, flavonoids, tannins compared to 
methanol extract and hexane extract.8,9 Third, 
in this ciplukan extract contains saponins 
substances that are not found in ciplukan plants 
abroad.16 Fourth, clinical and laboratory data 
support antifibrotic effects of ethanol extract 
of ciplukan herb for scleroderma. The addition 
of ciplukan herb has been proven to accelerate 
clinical improvement based on decreased MRSS 
values in assessing skin fibrosis. In general, 
standard scleroderma treatment needs longer 
time to reduce MRSS values from the baseline, 
up to 2 years.13,14 In this study, the reduction 
of MRSS to 6 points lower than the baseline 
was achieved within 3 months. We also found 
a significant decrease in serum P1NP level 
clinically and statistically as the evidence of 
fibrosis process of improvement.
Eventhough the correlation was weak 
between MRSS and P1NP levels, our finding 
supports the theory that P1NP has a role in skin 
fibrosis process of scleroderma patients who 
show an excessive synthesis of collagen and 
release its metabolite products to the circulation. 
We found no correlation between MRSS and the 
result of ESR value, serum BAFF and CD40L 
levels in both groups. ESR, as the biomarker 
for inflammation used in this study, failed to 
indicate the presence of inflammation process in 
scleroderma due to less sensitive. Further study 
using other inflammatory markers are needed to 
prove the anti-inflamation effects of Ciplukan 
herb. There were no significant changes of serum 
BAFF and sCD40L levels.
The outcome of this study was analyzed 
per protocol. Although there were 2 subjects 
excluded from the study, the number of our 
study subjects (29 and 30 for the treatment and 
the control group, respectively) still exceeded 
the minimum sample size from the calculated 
sample size, i.e. at least 27 subjects for each 
group. The number of samples in this study has 
met the criteria, thus the result of the research 
outcomes analysis is valid, with good research 
power (80%).
The ciplukan extract is suggested to 
have synergic effects as antifibrotic on skin 
scleroderma, by its antioxidant, antiinflammatory, 
antiproliferative effects, and saponins content in 
ciplukan herb may also have a similar effect 
to methotrexate action, with the end result 
of clinical improvement of scleroderma skin 
fibrosis.10-12,25-27
CONCLUSION
Our results suggested that administration 
of 3x250 mg per day dose of ciplukan herb 
extract as adjuvant therapy in scleroderma 
standard therapy for 12 weeks, was statistically 
significant and clinically important in alleviating 
skin fibrosis based on assessment of MRSS and 
P1NP levels.
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